Core Points - HI-VIEW RESOURCES INC. announced a non-brokered private placement of up to 4,800,000 units at a price of $0.10 per unit, aiming for gross proceeds of up to $480,000 [1][2] - Each unit consists of one common share and one transferable common share purchase warrant, with the warrant allowing the purchase of an additional share at $0.12 for 36 months [2] - Directors and officers may participate in the private placement, which is classified as a related party transaction and is expected to be exempt from certain formal requirements [3] - The net proceeds will be used for exploration activities and general corporate purposes, with a potential finder’s fee of up to 10% applicable [4] - HI-VIEW is focused on mineral exploration in Canada, holding a 100% interest in the Babine BC Copper-Gold property and other claims in the Toodoggone region, covering over 9,749 hectares [5]

Core Insights - Eton Pharmaceuticals has received FDA approval for KHINDIVI, the first and only hydrocortisone oral solution, aimed at pediatric patients with adrenocortical insufficiency [1][3][9] - The commercial launch of KHINDIVI is expected in the week of June 2, with projected combined peak sales of KHINDIVI and ALKINDI SPRINKLE exceeding $50 million annually [1][6] Product Details - KHINDIVI is formulated as a 1mg/ml oral solution, designed for easy dosing without the need for refrigeration or mixing, making it suitable for patients with swallowing difficulties [2][4] - The product is indicated for replacement therapy in pediatric patients aged five years and older with adrenocortical insufficiency [9] Market Context - There are over 5,000 pediatric patients in the U.S. diagnosed with adrenal insufficiency, highlighting a significant market opportunity for KHINDIVI [6] - Eton's existing commercial team will promote KHINDIVI alongside ALKINDI SPRINKLE, providing additional treatment options for patients and caregivers [5][7] Strategic Partnerships - KHINDIVI will be available exclusively through Anovo, a specialty pharmacy, which will also manage the Eton Cares Program to assist patients with prescription fulfillment and financial support [7][8] Company Overview - Eton Pharmaceuticals focuses on developing treatments for rare diseases and currently has eight commercial products, including KHINDIVI and ALKINDI SPRINKLE [41]

Core Points - Astrotech Corporation has appointed Jennifer Cañas as Chief Financial Officer effective May 22, 2025 [1] - The Board expressed confidence in Ms. Cañas' leadership and experience, highlighting her strong performance since joining the company [2] - Ms. Cañas has over 20 years of experience in senior financial roles, including her previous position as Controller at The Texas Water Company [2] - She is a Certified Public Accountant and graduated Cum Laude with a Bachelor of Science degree in accounting from the University of Houston – Clear Lake [3] - Ms. Cañas is committed to leading the team with integrity and aims to deliver value for shareholders [4] Company Overview - Astrotech Corporation is a mass spectrometry company that develops and commercializes scalable companies through its subsidiaries [4] - Subsidiaries include 1st Detect, AgLAB, Pro-Control, BreathTech, and EN-SCAN, each focusing on different markets such as security, agriculture, and environmental testing [4]

Financial Performance - Clear Blue Technologies reported Q1 2025 revenue of CAD 1,051,261, a 30% increase from CAD 808,553 in Q1 2024 [1] - Gross profit for Q1 2025 was CAD 551,601, representing a 63% increase compared to CAD 338,339 in Q1 2024 [5] - The gross margin percentage improved to 52% from 42% in the same quarter of the previous year [5] - Non-IFRS Adjusted EBITDA for the period was CAD (2,634,592), a 62% decrease from CAD (1,629,513) in the previous period [5] Market Trends and Opportunities - Clear Blue identifies three key themes for growth: the mainstream adoption of smart solar lighting, the transition away from diesel in Africa's telecom sector, and the expansion of satellite internet and IoT services [4][5] - The company is positioned to benefit from a projected CAD 25 million revenue opportunity over the next three years through its partnership with Eutelsat for satellite-powered community internet and IoT services [5] Operational Insights - As of March 31, 2025, bookings decreased to CAD 4,365,698, a 14% decline from CAD 5,071,105 as of December 31, 2024 [5] - Recurring revenue for Q1 2025 was CAD 217,662, down 28% from CAD 300,786 in Q1 2024 [5] - Cash as of March 31, 2025, was CAD 128,971, remaining stable through Q1 [5] Strategic Initiatives - The company has completed its financial restructuring, which was a significant effort by the management team, and is now focused on building a strong growth trajectory [6][7] - Clear Blue has expanded its product portfolio with three new products over the last two years, enhancing its market position [6]

Core Viewpoint - Houston American Energy Corp. has announced a reverse stock split at a ratio of 1-for-10 to increase the market price per share and meet NYSE listing requirements related to its acquisition of Abundia Global Impact Group, LLC [1][2][7] Group 1: Reverse Stock Split Details - The reverse stock split will be effective after market close on June 6, 2025, with trading on a split-adjusted basis starting June 9, 2025 [2] - The number of issued and outstanding shares will decrease from approximately 15,686,533 to about 1,568,653 shares [3] - Each stockholder's percentage ownership will remain unchanged, and no fractional shares will be issued [4] Group 2: Company Information - Houston American Energy Corp. is focused on the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties, primarily in the U.S. Permian Basin and Louisiana U.S. Gulf Coast region [7] - The trading symbol for the common stock will remain "HUSA," and a new CUSIP number will be assigned following the reverse stock split [5]

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Wintergreen Acquisition Corp. (NASDAQ: WTGUU, the “Company”) announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Capital Market (“NASDAQ”) and trade under the ticker symbol “WTGUU” beginning on May 29, 2025. Each unit consists of one ordinary share and one right to receive one-eighth (1/8th) of one ordinary share upon consummation of an initial business combination. Once ...

NETANYA, Israel, May 28, 2025 /PRNewswire/ -- TAT Technologies Ltd. (Nasdaq: TATT) (TASE: TATT) ("TAT" or the "Company"), a leading provider of products and services to the commercial and military aerospace and ground defense industries, announced today that it has commenced an underwritten public offering of ordinary shares. 1,625,000 ordinary shares are being offered by TAT and 2,525,000 ordinary shares are being offered by FIMI Opportunity V, L.P. and FIMI Israel Opportunity Five, Limited Partnership (th ...

Core Viewpoint - IMUNON, Inc. has successfully closed a private placement, raising approximately $3.25 million, with potential additional proceeds of up to $6.5 million from short-term warrants [1][3]. Group 1: Financial Details - The company sold 7,222,223 shares of common stock at a price of $0.45 per share, along with short-term warrants to purchase up to 14,444,446 additional shares [1]. - The total gross proceeds from the private placement are approximately $3.25 million before deducting fees and expenses [3]. - If fully exercised, the short-term warrants could provide an additional $6.5 million in gross proceeds [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes [3]. Group 3: Regulatory and Offering Details - The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and have not been registered under the Act [4]. - The offering was made only to accredited investors, and the company has agreed to file registration statements with the SEC for resale of the shares [4]. Group 4: Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments using non-viral DNA technology [6]. - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, which has completed multiple clinical trials [7]. - IMUNON is also advancing a COVID-19 booster vaccine (IMNN-101) and aims to leverage its technologies to address difficult-to-treat conditions [7].

MONTRÉAL, May 28, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) is pleased to announce that all of the nominees listed in its Management Proxy Circular dated April 15, 2025 were re-elected as directors at the Company’s Annual Meeting of Shareholders held today in Montréal. At the meeting, a ballot was conducted for the election of directors. According to proxies received and ballots cast, the following individuals were elected as directors of Dorel, with the following results: Name of N ...

CALGARY, Alberta, May 28, 2025 (GLOBE NEWSWIRE) -- Quorum Information Technologies Inc. (TSX-V: QIS) (“Quorum”), a North American SaaS Software and Services company providing essential enterprise solutions that automotive dealerships and Original Equipment Manufacturers (“OEMs”) rely on for their operations, released its results today for the first quarter of 2025, ended March 31, 2025. Financial references are expressed in Canadian dollars unless otherwise indicated. Please refer to the MD&A and Financial ...